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A second amplification, using nested primers, resulted in the
appearance of mRNA-derived K19 product in normal nodes as
well as nodes from cancer patients. Thus, there is a low level of
K19 mRNA in normal nodes, and the potential of RT-PCR in the
staging of breast cancer is therefore limited by the specificity of
the tumour marker.
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Mutations at codon 974 of the DPYD gene are a rare
event
Sir
We regret to inform you of an error made in a recently published
article in the British Journal of Cancer (75: 178-179). 'Mutations
at codon 974 ofthe DPYD gene are -a rare event' from Ridge et al
(1997). In this study, Ridge et al attempted to determine the
frequency of a mutation originally described by our laboratory in
1995 (abstract presented at the American Association of Cancer
Research, AACR). Unfortunately, the authors of this study misin-
terpreted the position ofthe mutation [A (control) to T (mutation)]
originally localized at position 2921 in the open reading frame of
dihydropyrimidine dehydrogenase cDNA. When translated, this
mutation results in an Asp to Val substitution corresponding to
codon 949, not to codon 974 as reported by Ridge et al. The posi-
tion ofthe mutation reported in the AACR abstract was based on a
complete human DPD cDNA amplified using primers designed
against bovine liver cDNA (Figure 1). Both the original
numbering system and the codon number (949) were presented at
the 1995 AACR meeting (Albin N et al (1995) Proc Am Assoc
CancerRes 36: 211).
After a careful review of this article, we have determined that
Ridge et al assigned the first adenosine nucleotide in the initiating
methionine as the number 1 position. This resulted in the incorrect
assignment ofcodon 974 as the site ofthe mutation (Figure 1). We
concur with Ridge et al that the frequency ofthis mutation should
be determined in the population and will therefore forward a copy
of this letter to Ridge et al, along with an offer to provide any
information necessary to correct this study.
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1 Bovine primer 1
5' ACTTTCGTCTCTGGCTGAAGCCTGAGGACGCAAGGAGGGTTlGTCACTGGCAGACTCGAGACTGTAGGCACTGCC ATG... 3'
Met
Original numbering system T
used in the 1995 AACR abstract Ridge et al (1997)
Figure 1 The bovine primer (bold and underlined) used to PCR amplify the 5' end of human lymphocyte DPD cDNA. The original numbering system assigned
the 5' end of the bovine primer as the number 1 position, with the mutation ultimately corresponding to position 2921, as originally presented in the abstract.
Ridge et al (1997) assigned the first adenosine nucleotide in the initiating methionine as the number 1 position and therefore localized the mutation to the wrong
codon (974 instead of 949)
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